Loading...
Loading...
Contributors:
Dataset URI:
10.5281/zenodo.18251668Human induced pluripotent stem cell (hPSC)-derived cardiomyocytes provide a human model to discover compounds that protect the heart during anthracycline chemotherapy. We used hPSC-derived cardiac monolayers to screen an Open Drugs library of 2,906 compounds to identify molecules that prevent doxorubicin-induced cardiomyocyte death. An orthogonal screen of 129 compounds identified as cardioprotective was performed in MCF7 breast cancer cells and MCF10A breast epithelial cells to ensure candidates did not interfere with doxorubicin’s anti-neoplastic activity or exert overt toxicity to non-cancerous, proliferative cells. Two compounds with cardioprotective effects (Cilnidipine and 3,3’-Diindolymethane) were selected – based on efficacy, chemical properties, and mechanism – for structure-activity relationship analyses to improve cardioprotection. Although some analogues showed increased potency in monolayers, validation in 3D hPSC-derived cardiac organoids revealed compromised contractility at cardioprotective doses. Here, we provide the drug screen dataset in raw and processed forms.
Keyword(s):
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
No Associated Publication Data Available
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)